百济神州(06160.HK)公布三项关键性临床试验之长期有效性及安全性结果
百济神州(06160.HK)公布,公司在2021年第26届欧洲血液学协会(EHA2021)线上大会上公布其血液学项目中的三项关键试验的长期随访结果,包括口头报告抗PD-1抗体药物百泽安(替雷利珠单抗)用於治疗复发或难治性(R/R)经典型霍奇金淋巴瘤(cHL)的2期试验数据,海报展示两项BTK抑制剂百悦泽(泽布替尼)用於治疗R/R套细胞淋巴瘤(MCL)和R/R慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)的2期试验数据,结果显示上述三项关键性临床试验的长期有效性和安全性结果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.